Atea Pharmaceuticals (NASDAQ:AVIR) is a biopharmaceutical company focused on the discovery, development, and commercialization of antiviral therapeutics for serious viral infections. Their portfolio is primarily geared towards addressing unmet medical needs in diseases caused by the hepatitis C virus, dengue, respiratory syncytial virus, and COVID-19 among others. With a strong emphasis on innovation, Atea is dedicated to pushing the boundaries of science to create effective treatments that can significantly improve patients' lives. Their objectives include advancing their current drug candidates through clinical trials, expanding their research into new antiviral targets, and forging strategic partnerships to enhance their reach and impact in the global healthcare market.